Search for Clinical Trial Results
Leiomyomatosis - 46 Studies Found
Status | Study |
Active, not recruiting |
Study Name: French National Registry of Rare Peritoneal Surface Malignancies Condition:
|
Recruiting |
Study Name: Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM) Condition: Lymphangioleiomyomatosis Date: 2006-12-20 Interventions:
|
Completed |
Study Name: Pulmonary Rehabilitation in Lymphangioleiomyomatosis Condition: Lymphangioleiomyomatosis Date: 2013-12-04 Interventions: Other: Pulmonary Rehabilitation |
Completed |
Study Name: The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1) Condition: Pulmonary Lymphangioleiomyomatosis Date: 2014-04-15 Interventions: Drug: Saracatinib Saracatinib is escalated as follows: Three dose levels will be administered for 1 mont |
Completed |
Study Name: Trial of Aromatase Inhibition in Lymphangioleiomyomatosis Condition: Lymphangioleiomyomatosis Date: 2011-05-11 Interventions:
|
Completed |
Study Name: A Study to Determine the Effectiveness of Escalating Doses of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis Condition: Lymphangioleiomyomatosis Date: 2010-01-28 Interventions: Drug: Everolimus |
Recruiting |
Study Name: A Study of Nintedanib for LymphAngioleioMyomatosis (LAM) Condition: Lymphangioleiomyomatosis Date: 2016-10-07 Interventions: Drug: Nintedanib Other Name: OFEV |
Recruiting |
Study Name: Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis Condition: Lymphangioleiomyomatosis Date: 2013-02-23 Interventions:
|
Recruiting |
Study Name: Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis Condition: Pulmonary Lymphangioleiomyomatosis Date: 2016-03-31 Interventions: Drug: saracatinib Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject wi |